Risultati di ricerca
24 mag 2024 · Pfizer wins pause on Moderna's COVID-19 patent lawsuit. April 12, 2024. The latest international Moderna Inc news and views from Reuters - one of the world's largest news agencies.
5 giorni fa · Analyst Recommendations on Moderna, Inc. Moderna Insider Sold Shares Worth $1,909,863, According to a Recent SEC Filing. May. 20. MT. Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing. May. 17. MT. Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program. May. 17.
5 giorni fa · Σάββας Καλεντερίδης: Ο Πούτιν σε παγίδα, η ρωσική "αρκούδα" στο δόκανοΟ στρατηγικός αναλυτής, συγγραφέας ...
- 48 min
- 43,9K
- Σάββας Καλεντερίδης
5 giorni fa · Moderna, Inc. è un'azienda biotecnologica specializzata nella ricerca e nello sviluppo di terapie e vaccini per il trattamento di malattie oncologiche, infettive, autoimmuni e cardiovascolari. Il fatturato per tipologia di ricavi è ripartito come segue: - ricavi da vendite di prodotti (95,7%); - entrate da sovvenzioni (4%); - ricavi da accordi di collaborazione (0,3%).
4 giorni fa · Moderna last announced its earnings results on May 2nd, 2024. The reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. The company earned $167 million during the quarter, compared to analyst estimates of $93.26 million. Its quarterly revenue was down 91.0% on a year-over-year basis.
3 giorni fa · 3.48%. -13.12%. -15.11%. -308.07%. Upgrade. Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual ( 10-K) and quarterly ( 10-Q) reports submitted to the Securities and Exchange Commission (SEC). Financial ratios and metrics for Moderna (MRNA). Includes annual, quarterly and trailing numbers with full history ...
3 giorni fa · According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $126.46, with a high forecast of $231.00 and a low forecast of $60.00. The consensus rating for Moderna stock is Hold based on the current 2 sell ratings, 9 hold ratings and 6 buy ratings for MRNA.
